Braingaze

Braingaze is a clinical-grade AI platform that leverages patented eye-tracking technology to provide objective diagnostic support for neurodevelopmental and neurodegenerative disorders. The technical architecture revolves around the analysis of 'microsaccades'—involuntary, microscopic eye movements—which are processed via proprietary machine learning models to detect cognitive markers associated with ADHD, Alzheimer’s, and Dyslexia. By 2026, Braingaze has solidified its position in the market as a primary non-invasive alternative to subjective clinical questionnaires, offering a 90% accuracy rate in differentiating cognitive phenotypes. The system utilizes standard high-frequency infrared sensors or high-resolution webcams to capture data, which is then processed in a secure cloud environment to generate clinical reports within minutes. Its utility extends beyond diagnosis into longitudinal patient monitoring, allowing clinicians to track the efficacy of pharmacological treatments through objective data points. As a CE-marked medical device, it bridges the gap between traditional neurology and modern AI, catering to hospitals, private clinics, and educational institutions globally.